Genetic Technologies Ltd (ASX: GTG) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Genetic Technologies Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Genetic Technologies Ltd (ASX: GTG)
Latest News
⏸️ Investing
Market wipeout: Stocks crushed in $24 billion rush for the exits
⏸️ Investing
4 stocks soaring on the ASX today
⏸️ Investing
Genetic Technologies Limited soars 30%: Here's why
GTG ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Genetic Technologies Ltd
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Anthony Hartman | Non-Executive Director | May 2025 |
Mr Hartman has over 20 years of experience in financial services in Australia, NZ, UK, EU, KH and North America. He has held positions with such firms as JP Morgan Investment Management, Citigroup Inc and Macquarie Group Ltd in financial services. Anthonys experience has been in listed markets in sales, discretionary portfolio management and structured situations. He has also been involved in private equity in listed and unlisted companies in a variety of diverse industries. Anthony is a current director of ASX listed Australian Bond Exchange Holdings Ltd.
|
| Mr Michael Walker | Executive ChairmanManaging Director | May 2025 |
Mr Walker brings over 20 years of leadership and compliance experience across industries, with a focus on regulatory licensing and financial services. He is the Founder and Investment Manager of Walker Capital, a boutique wealth management firm in discretionary managed portfolios and a Fixed Income Fund. Michael is also the Director and CEO of Ellerfield Financial Planning. In addition, Michael serves as one of the Responsible Managers of Walker Capital Private Wealth Pty Ltd, which operates under an Australian Financial Services Licence (AFSL).
|
| Mr William Anthony Musgrave | Non-Executive Director | May 2025 |
Mr Musgrave, has 20 years of commercial experience to his role as a director at GTG. Before practicing law, he built a career in marketing, developing communications skills .
|
| Mr Mark Ziirsen | Chief Financial OfficerCompany Secretary | Jul 2024 |
-
|
| Ms Priyamvada Sanjay Rasal (Pia) | Joint Company Secretary | May 2025 |
-
|
| Mr Simon Morriss | Chief Executive Officer | Feb 2021 |
-
|
| Carl Stubbings | Chief Commercial Officer |
-
|
|
| Simon Morriss | Chief Executive Officer |
-
|
|
| Kevin Camilleri | Chief Executive Officer EasyDNA |
-
|
|
| Kathryn Andrews | Chief Financial Officer |
-
|
|
| Mark Ziirsen | Chief Financial OfficerCompany Secretary |
-
|
|
| Priyamvada Sanjay Rasal (Pia) | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 103,434,943 | 71.13% |
| Mr Warwick Wright | 2,440,000 | 1.68% |
| MJGD Nominees Pty Ltd | 2,008,494 | 1.38% |
| Doma 193 Pty Ltd <Doma 193 A/C> | 1,445,514 | 0.99% |
| Rip Opportunities Pty Ltd <Pir Super Fund A/C> | 1,250,000 | 0.86% |
| Irwin Biotech Nominees Pty Ltd <Bioa A/C> | 758,494 | 0.52% |
| Mr Lei Da Tao | 685,000 | 0.47% |
| Irwin Biotech Nominees P/L <Bioa A/C> | 679,209 | 0.47% |
| Miss Susan Spiteri | 557,724 | 0.38% |
| AP 300 Pty Ltd <AP Invest A/C> | 480,400 | 0.33% |
| Monument Hill Pty Ltd | 420,001 | 0.29% |
| Mrs Helen Kamer and Mr Benjamin Kamer <Kamer Super Fund A/C> | 400,000 | 0.28% |
| Ms Carol Yan Lu | 400,000 | 0.28% |
| Alwoonee Pty Ltd <The O'Connor Super A/C> | 388,959 | 0.27% |
| Mr Wenbo Liu | 377,358 | 0.26% |
| Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 354,066 | 0.24% |
| Mr John Christopolous <Chrisand Family A/C> | 348,000 | 0.22% |
| Aquasafe Investments Pty Ltd <White Superfund A/C> | 306,081 | 0.21% |
| Mr Kar Leong Chong | 300,000 | 0.21% |
| Mr Md Touhidur Rahman | 300,000 | 0.21% |
| Whalecorp Pty Ltd <Whalecorp Pty Ltd S/F A/C> | 300,000 | 0.21% |
